“[...] atypical complaints and symptoms outside the head and neck region can indicate (distant) metastasis [...]”

BUFFALO, NY- December 22, 2023 – A new research perspective was published in Oncoscience (Volume 10) on August 14, 2023, entitled, “Squamous cell carcinoma of the oral cavity – follow up treatment and distant metastatic behavior.”

Up to 90% of tumors in the head and neck region are squamous cell carcinomas (SCC). SCC can develop in different anatomical sections of the head

“In the United States, 288,300 new cases of prostate cancer are estimated for 2023 [...]”

BUFFALO, NY- December 8, 2023 – A new research perspective was published in Oncoscience (Volume 10) on November 30, 2023, entitled, “Evolving insights in blood-based liquid biopsies for prostate cancer interrogation.”

During the last decade, blood sampling of cancer patients aimed at analyzing the presence of cells, membrane-bound vesicles, or molecules released by primary tumors or metastatic

“One limitation [of Cre-LoxP], the focus of this editorial, is the potential loss of fidelity of Cre recombinase expression especially in the context of modeling cancer in mice.”

BUFFALO, NY- December 1, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on November 14, 2023, entitled, “Be mindful of potential pitfalls when using the Cre-LoxP system in cancer research.”

In this new editorial, researchers Piotr Czarnota and Jaroslaw Cisowski from the Jagiellonian

“In this ESCA study, the possibility of an immune response that selected for tumor cells lacking the DDX53 CTA is discussed.”

BUFFALO, NY- November 17, 2023 – A new research paper was published in Oncoscience (Volume 10) on November 10, 2023, entitled, “An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen.”

T-lymphocytes have been implicated in facilitating a pro-inflammatory, pro-tumorigenic microenvironment that worsens

“The patient was managed with ripretinib and surgical resection of progressing lesions at multiple time points which led to extended clinical benefit.”

BUFFALO, NY- November 3, 2023 – A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, “Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery.”

Ripretinib is a tyrosine kinase

“The majority of wound infections often manifest themselves immediately postoperatively, so close followup should take place […]”

BUFFALO, NY- October 20, 2023 – A new research perspective was published in Oncoscience (Volume 10) on October 4, 2023, entitled, “Diagnosis and management of postoperative wound infections in the head and neck region.”

In everyday clinical practice at a department for oral and maxillofacial surgery, a large number of surgical procedures in the head

“Several ongoing trials hope to further elucidate the role of lurbinectedin in highgrade neuroendocrine neoplasms […]”

BUFFALO, NY- October 6, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on June 14, 2023, entitled, “Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer.”

In their new editorial, researchers Deepak Bhamidipati and Vivek Subbiah from the Sarah Cannon Research Institute discuss lurbinectedin

“We have summarized some of our findings regarding the response of various subsets of CRC to kinase inhibitors […].”

BUFFALO, NY- September 22, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on June 27, 2023, entitled, “Kinase-targeted therapy in subsets of colorectal cancer.”

In this new editorial, researchers Patricia M. Gomez Barila and Jan Paul Medema from the University of Amsterdam and Amsterdam University Medical Centers discuss colorectal cancer

“While vaccination has been successful for the general population, it is crucial not to overlook the needs of immunocompromised individuals.”

BUFFALO, NY- September 8, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on September 1, 2023, entitled, “Exiting the pandemic together: achieving global immunity and equity.”

In this new editorial, researchers Yuxin Ying, Jola Bytyci and Lennard YW Lee from Oxford Medical School discuss their recent investigation

“One can expect that artificial intelligence (AI) will play some role in the future drug development.”

BUFFALO, NY- August 25, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on August 17, 2023, entitled, “Cancer drug development yesterday, today and tomorrow.” In this new editorial, researchers Elzbieta Izbicka and Robert T. Streeper from New Frontier Labs discuss the history of cancer drug development and how it has evolved over time. The editorial also

“Proton therapy […] seems to have decisive advantages with regard to the long-term survival of [adenoid cystic carcinoma] […]”

BUFFALO, NY- August 4, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on June 28, 2023, entitled, “Adenoid cystic carcinoma of the head and neck – treatment strategies of a highly malignant tumor with variable localizations.”

In this new editorial, researchers Florian Dudde, Kai-Olaf Henkel and Filip Barbarewicz from the Army Hospital

“[Machine learning] has the potential to transform early cancer detection in primary care […]”

—

BUFFALO, NY- July 21, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on June 9, 2023, entitled, “Transforming early cancer detection in primary care: harnessing the power of machine learning.”

Cancer remains a significant global health burden, and early detection plays a crucial role in improving patient outcomes. Primary care settings serve as frontline

“[…] in many cases [of chronic sinusitis] only symptom control is achieved.”

—

BUFFALO, NY- July 14, 2023 – A new research perspective was published in Oncoscience (Volume 10) on May 27, 2023, entitled, “Think outside the box – atypical infections in chronic sinusitis.”

Inflammations of the paranasal sinuses represent a common clinical picture. The annual prevalence of chronic sinusitis in Europe is up to 10%. Sinusitis can be divided into acute and chronic forms. In particular,

“Approaches targeted to prevent this post-therapy cancer cell repopulation should be uncovered to prevent tumor relapse and thus increase overall survival from this devastating disease.”

BUFFALO, NY- June 23, 2023 – A new research perspective was published in Oncoscience (Volume 10) on June 1, 2023, entitled, “Cancer cell repopulation after therapy: which is the mechanism?”

The past two decades have brought great progress in the treatment of cancer as patients with the disease

“UPR [unfolded protein response] modulation in combination with conventional chemotherapeutic drug treatments of ovarian cancer patients could represent an interesting therapeutic strategy […]”

BUFFALO, NY- May 26, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on May 11, 2023, entitled, “UPR-induced ovarian cancer cell fusion: a mechanism favoring drug resistance?”

In this editorial, researchers Melisa

“[…] developing targeted therapies that specifically inhibit ATAD3A in cancer cells while sparing normal cells will be a challenging but critical task.”

BUFFALO, NY- April 28, 2023 – A new research perspective was published in Oncoscience (Volume 10) on April 4, 2023, entitled, “Mitochondrial regulator ATAD3A: a molecular determinant favoring head and neck cancer development.”

In addition to their role in energy metabolism,

“[…] DPE analysis may have an important role in improving the diagnosis and management of CRC.”

BUFFALO, NY- April 7, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on March 23, 2023, entitled, “New method of clustering colorectal cancer patients using differential presence of exons (DPE) sequencing.”

Colorectal cancer (CRC) is a heterogeneous disease that occurs in the colon and the rectum, parts of the

“We call upon the oncology community to embrace these results to avoid overtreatment of DCIS patients.”

—

BUFFALO, NY- February 17, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on January 30, 2023, entitled, “HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!”

HER2 is more frequently overexpressed in ductal carcinoma in situ (DCIS) than in invasive breast cancer.

“As anticipated, we found that the onset of leukemia was significantly accelerated in Idh2R140Q/NHD13 double transgenic mice […]”

—

BUFFALO, NY- January 23, 2023 – A new research perspective was published in Oncoscience (Volume 9) on October 24, 2022, entitled, “A murine model for human early/immature T-cell precursor acute lymphoblastic leukemia (EITP ALL).”

In this research perspective, researchers Vijay Negi and Peter D. Aplan

“Though meningioma patients often see favorable oncological outcomes, many tumors still recur post-surgically.”

BUFFALO, NY- January 17, 2023 – A new research paper was published in Oncoscience (Volume 9) on December 9, 2022, entitled, “Association between tumor mutations and meningioma recurrence in Grade I/II disease.”

Meningiomas are common intracranial tumors with variable prognoses not entirely captured by commonly used